← Back to Search

Behavioral Intervention

Video-based Exercise Prehabilitation for Pancreatic Cancer

Phase 3
Recruiting
Led By An Ngo-Huang, DO
Research Sponsored by M.D. Anderson Cancer Center
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up thorugh study completion; an average of 1 year.
Awards & highlights

Study Summary

This trial tests if exercise can improve outcomes for people with pancreatic cancer who are receiving chemotherapy.

Who is the study for?
This trial is for adults over 18 with resectable pancreatic cancer, scheduled for chemo followed by surgery. They must be able to do fitness tests and follow the Tele-PancFit exercise program, have Wi-Fi at home for remote sessions, and not be in severe pain or have unstable heart/lung conditions.Check my eligibility
What is being tested?
The study compares usual care with a tele-supervised resistance exercise program (Tele-PancFit) during chemotherapy to see if it improves outcomes for patients undergoing treatment for pancreatic cancer.See study design
What are the potential side effects?
While specific side effects are not listed, typical risks of resistance exercises may include muscle soreness, fatigue, and potential strain on the heart or lungs especially in those with pre-existing conditions.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~thorugh study completion; an average of 1 year.
This trial's timeline: 3 weeks for screening, Varies for treatment, and thorugh study completion; an average of 1 year. for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Safety and adverse events (AEs)

Trial Design

2Treatment groups
Experimental Treatment
Group I: Group B-Tele-supervised resistance exercisesExperimental Treatment1 Intervention
Participants will take part in a monitored exercise program. The study team will provide more instructions and information about the program
Group II: Group A-Enhanced Usual CareExperimental Treatment1 Intervention
Participants will be given general recommendations to increase physical activity and improve nutrition before surgery.

Research Highlights

Information in this section is not a recommendation. We encourage patients to speak with their healthcare team when evaluating any treatment decision.
Mechanism Of Action
Side Effect Profile
Prior Approvals
Other Research
Common treatments for pancreatic cancer include surgery, chemotherapy, and radiation therapy. Surgery aims to remove the tumor and surrounding tissues, potentially offering a cure in early-stage disease. Chemotherapy uses drugs to kill cancer cells or stop their growth, often by damaging their DNA or interfering with cell division. Radiation therapy uses high-energy rays to target and destroy cancer cells. Supportive care, such as supervised exercise programs, plays a crucial role by improving physical fitness, reducing treatment-related side effects like fatigue, and potentially enhancing the effectiveness of chemotherapy. This holistic approach is vital for pancreatic cancer patients as it can improve overall quality of life and treatment outcomes.

Find a Location

Who is running the clinical trial?

M.D. Anderson Cancer CenterLead Sponsor
2,992 Previous Clinical Trials
1,792,535 Total Patients Enrolled
An Ngo-Huang, DOPrincipal InvestigatorM.D. Anderson Cancer Center

Media Library

Tele-supervised resistance exercises (Behavioral Intervention) Clinical Trial Eligibility Overview. Trial Name: NCT05836870 — Phase 3
Pancreatic Cancer Research Study Groups: Group A-Enhanced Usual Care, Group B-Tele-supervised resistance exercises
Pancreatic Cancer Clinical Trial 2023: Tele-supervised resistance exercises Highlights & Side Effects. Trial Name: NCT05836870 — Phase 3
Tele-supervised resistance exercises (Behavioral Intervention) 2023 Treatment Timeline for Medical Study. Trial Name: NCT05836870 — Phase 3
~80 spots leftby Dec 2030